Vanylglycol
|
Basic information |
| Metabolite name | Vanylglycol |
 | HMDB0001490 |
 |
C05594 |
 |
10805 |
| Synonyms | methoxy-hydroxyphenly glycol; |
| No. of studies | 7 |
|
Basic information |
| Metabolite name | Vanylglycol |
| HMDB0001490 |
|
C05594 |
|
10805 |
| Synonyms | methoxy-hydroxyphenly glycol; |
| No. of studies | 7 |
|
Relationship between Vanylglycol and depression (count: 7) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M011 | Type4 | placebo-treated responder group vs. non-responder group | Serum | Human | Unknown |
| Study M1098 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M158 | Type1 | depressed group vs. control group | Saliva | Human | Up |
| Study M158 | Type4 | SSRIs treated responder group vs. non-responder group at baseline | Saliva | Human | Up |
| Study M574 | Type1 | CMS group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M712 | Type1 | depression group vs. control group | Hippocampus | Cynomolgus monkey | Down |
| Study M848 | Type1 | CRS group vs. control group | Serum | C57BL/6 J mouse | Down |
| Study M848 | Type2 | CRS + dexamethasone group vs. CRS group | Serum | C57BL/6 J mouse | Up |
| Study M898 | Type1 | end-stage renal disease with depression group vs. end-stage renal disease without depression group | Serum | Human | Up |